Similar articles for PMID: 29094028

Year	Number of Results
2010	1
2011	2
2012	1
2013	1
2014	1
2015	4
2016	6
2017	5
2018	7
2019	16
2020	11
2021	12
2022	7
2023	2
2024	0

1

Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer.

Kim HS, Jang JY, Han Y, Lee KB, Joo I, Lee DH, Kim JR, Kim H, Kwon W, Kim SW. Kim HS, et al. Ann Surg Treat Res. 2017 Oct;93(4):186-194. doi: 10.4174/astr.2017.93.4.186. Epub 2017 Sep 28. Ann Surg Treat Res. 2017. PMID: 29094028 Free PMC article.

2

Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.

Javed AA, Wright MJ, Siddique A, Blair AB, Ding D, Burkhart RA, Makary M, Cameron JL, Narang A, Herman J, Zheng L, Laheru D, Weiss MJ, Wolfgang C, He J. Javed AA, et al. J Gastrointest Surg. 2019 Jan;23(1):112-121. doi: 10.1007/s11605-018-3966-8. Epub 2018 Sep 21. J Gastrointest Surg. 2019. PMID: 30242644 Free PMC article.

3

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.

Janssen QP, O'Reilly EM, van Eijck CHJ, Groot Koerkamp B. Janssen QP, et al. Front Oncol. 2020 Jan 31;10:41. doi: 10.3389/fonc.2020.00041. eCollection 2020. Front Oncol. 2020. PMID: 32083002 Free PMC article.

4

Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.

Barenboim A, Lahat G, Geva R, Nachmany I, Nakache R, Goykhman Y, Brazowski E, Rosen G, Isakov O, Wolf I, Klausner JM, Lubezky N. Barenboim A, et al. Eur J Surg Oncol. 2018 Oct;44(10):1619-1623. doi: 10.1016/j.ejso.2018.07.057. Epub 2018 Aug 2. Eur J Surg Oncol. 2018. PMID: 30146251

5

Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.

Yoo C, Kang J, Kim KP, Lee JL, Ryoo BY, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Hwang DW, Song KB, Lee JH, Kim SC. Yoo C, et al. Oncotarget. 2017 Jul 11;8(28):46337-46347. doi: 10.18632/oncotarget.17940. Oncotarget. 2017. PMID: 28564637 Free PMC article.

6

Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.

Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Janssen QP, et al. J Natl Cancer Inst. 2019 Aug 1;111(8):782-794. doi: 10.1093/jnci/djz073. J Natl Cancer Inst. 2019. PMID: 31086963 Free PMC article.

7

Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.

Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Mellon EA, et al. Acta Oncol. 2015 Jul;54(7):979-85. doi: 10.3109/0284186X.2015.1004367. Epub 2015 Mar 3. Acta Oncol. 2015. PMID: 25734581

8

Prognostic Value of Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Carcinoma Followed by Pancreatectomy with Portal Vein Resection and Reconstruction with Venous Allograft.

Huang JC, Pan B, Wang HX, Chen Q, He Q, Lyu SC. Huang JC, et al. J Clin Med. 2022 Dec 12;11(24):7380. doi: 10.3390/jcm11247380. J Clin Med. 2022. PMID: 36555996 Free PMC article.

9

Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.

Hirono S, Kawai M, Okada KI, Miyazawa M, Shimizu A, Kitahata Y, Ueno M, Yamaue H. Hirono S, et al. Pancreas. 2016 Nov;45(10):1438-1446. doi: 10.1097/MPA.0000000000000634. Pancreas. 2016. PMID: 27088490

10

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.

Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS. Murphy JE, et al. JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329. JAMA Oncol. 2018. PMID: 29800971 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

61 results

Results by year